Company news
GRI Bio, Inc. news in 2025
GRI Bio, Inc.'s news releases, calls and decks from 2025, newest first.
GRI Bio Announces Closing of $8.0 Million Public Offering
December 12, 2025
GRI Bio Announces Pricing of $8,000,000 Million Public Offering
December 11, 2025
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
December 10, 2025
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
September 11, 2025
GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
August 14, 2025
GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment
July 31, 2025
GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
July 31, 2025
GRI Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
July 22, 2025
GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
July 1, 2025
GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
June 26, 2025
GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results
May 22, 2025
GRI Bio to Participate in the Virtual Investor Closing Bell Series
May 21, 2025
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
May 16, 2025
GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025
May 15, 2025
GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
May 8, 2025
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
May 7, 2025
GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference
April 16, 2025
GRI Bio Announces Closing of $5.0 Million Public Offering
April 2, 2025
GRI Bio Announces Pricing of $5.0 Million Public Offering
April 1, 2025
GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
April 1, 2025
GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan
March 31, 2025
GRI Bio Participates in a Virtual Investor CEO Connect Segment
March 18, 2025
GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
March 17, 2025
GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule
March 11, 2025
GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
February 19, 2025
Decks in 2025
- Investor Presentation (August 2025)
Investor deck · 23 slides · Aug 20, 2025